复苏来得如此之快!2025年,CXO行业的至暗时刻似乎已经过去。行业老大哥药明康德率先交上优异的成绩单,2025年第一季度净利润增速高达89%。康龙化成、凯莱英也接连赶上,同期净利润增速分别达到32.54%、15.83%。但在我国医药外包(CXO)行业一片欣欣向荣之际,泰格医药似乎“掉队了”。2024年,泰格医药营收为66.03亿元,同比减少10.58%,净利润为4.05亿元,降幅达到80%。这一...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.